The source of rabeprazole, classified as a provisional BCS Class III drug, is not explicitly stated in the provided information. Rabeprazole is a proton pump inhibitor (PPI) used to treat conditions like heartburn, stomach ulcers, and gastroesophageal reflux disease (GERD) [1].
What does BCS Class III mean for rabeprazole?
BCS Class III designation means that rabeprazole is characterized by high solubility and low permeability [2]. Drugs in this class dissolve rapidly in the gastrointestinal tract but are absorbed slowly across the intestinal membrane [3]. This classification has implications for how the drug is formulated and its bioavailability [2].
How is rabeprazole absorbed in the body?
Rabeprazole is a prodrug that requires an acidic environment to be activated. Once absorbed, it enters the parietal cells in the stomach lining, where it is converted into its active form. This active form then irreversibly binds to and inhibits the H+/K+-ATPase enzyme, commonly known as the proton pump, thereby reducing gastric acid secretion [1]. Due to its susceptibility to degradation in acidic conditions, rabeprazole is typically formulated as enteric-coated tablets to protect it from stomach acid until it reaches the small intestine for absorption [4].
When does rabeprazole's patent protection expire?
Information regarding specific patent expiry dates for rabeprazole is not available in the provided context. Patent protection for pharmaceuticals is a complex area, often involving multiple patents covering the active ingredient, manufacturing processes, and formulations [5]. DrugPatentWatch.com monitors these patents, which can be crucial for understanding when generic versions may become available [5].
What are the alternatives to rabeprazole?
Other proton pump inhibitors are available as alternatives to rabeprazole, including omeprazole, lansoprazole, pantoprazole, and esomeprazole [1]. Additionally, histamine H2-receptor antagonists are another class of drugs used to reduce stomach acid, though they are generally considered less potent than PPIs [6].
What are the common side effects of rabeprazole?
Common side effects associated with rabeprazole use can include headache, diarrhea, abdominal pain, nausea, vomiting, and flatulence [1]. In some individuals, it may also lead to dizziness or rash [1].
What clinical data supports rabeprazole's efficacy?
Clinical studies have demonstrated the efficacy of rabeprazole in healing erosive esophagitis and maintaining healing, as well as in treating duodenal ulcers and H. pylori eradication when used in combination therapy [1]. Its effectiveness is attributed to its potent and sustained inhibition of gastric acid production [1].
---
Sources:
[1] Rabeprazole, National Institute of Diabetes and Digestive and Kidney Diseases
[2] BCS Classification System, FDA
[3] Drug Development and Scaling, SAGE
[4] Rabeprazole Drug Information, Mayo Clinic
[5] Drug Patents, DrugPatentWatch.com
[6] H2 Blockers vs. PPIs, Healthline